Shilpa Medicare's Marketing Partner Launches First Ready-to-Use Pemetrexed Injection in US Market

Shilpa Medicare has announced that its marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU® (Pemetrexed injection 10 mg/mL), the first ready-to-use pemetrexed formulation in the US market. The product, which has already been granted permanent J-code by CMS, is used in the treatment of non-small cell lung cancer and mesothelioma. This novel injection eliminates the need for refrigeration or preparation steps, offering hospitals and clinics improved pharmacy efficiency. The product is currently available in 100mg/10mL and 500 mg/50mL sizes, with a 1000mg/100mL size planned for introduction. IQVIA estimates U.S. annual sales for pemetrexed to be $287 million as of February 2024.